HIV and Hepatitis.com Coverage of the
14th Annual Conference on Retroviruses
and Opportunistic Infections (14th CROI)
February 25 - 28, 2007, Los Angeles, CA
Metabolic and Cardiovascular Complications of HAART

HIV Positive Patients Respond Less Well to Lipid-lowering Therapy  - 3/30/07

No Significant Body Composition Differences between Patients Treated with Atazanavir vs Atazanavir/ritonavir  - 3/20/07

High Dietary Fat Consumption Is Associated with Elevated Serum Lipids in HIV Positive Individuals  - 3/16/07

Ezetimibe (Zetia) May Benefit HIV Positive Patients Unable to Take Statins to Lower LDL Cholesterol  - 3/09/07

TH9507 Growth Hormone-releasing Factor Decreases Visceral Abdominal Fat and Improves Lipid Profiles  - 3/09/07

Compared to Efavirenz, Lopinavir/Ritonavir Has Less Lipoatrophy When Given with NRTI  - 3/09/07

Cardiovascular Risk Factors, Lipoatrophy, and Lipid Profiles in SMART Study  - 3/06/07

Alendronate (Fosamax) Is Effective Therapy for Bone Loss in HIV Positive Men and Women  - 3/06/07

Significant Sparing of Lipoatrophy Results from Treatment of HIV Patients with Kaletra + Combivir Induction followed by Kaletra Monotherapy Compared with Sustiva + Combivir - 3/02/07












































14th croi